健康成人接种mRNA新冠疫苗后NT-proBNP短暂升高
该纵向生物标志物分析纳入83名接种两剂mRNA新冠疫苗的健康成人军人,于2021年4月至12月多时间点采集血清。结果显示第二剂后14天内NT-proBNP几何均值36.2 pg/mL(p<0.0001),近49%参与者相对基线升高超1.5倍,但无人超过450 pg/mL阈值,肌钙蛋白无变化。
要点
- 第二剂mRNA新冠疫苗后14天内NT-proBNP出现显著但短暂的亚临床升高。
- 近49%参与者NT-proBNP相对升高超过个体基线1.5倍,但无人超过450 pg/mL。
- 所有评估的14天间期肌钙蛋白水平均无变化。
核心结论
- 健康成人接种mRNA新冠疫苗与NT-proBNP短期亚临床升高相关,尤其在第二剂后,不提示明显心血管损伤。
研究设计与样本
- 纵向生物标志物分析,纳入83名接种两剂mRNA新冠疫苗的健康成人军人,2021年4月至12月多时间点采集血清。
主要发现
- 第二剂后14天内NT-proBNP几何均值36.2 pg/mL(p<0.0001),呈显著但短暂升高。
- 近49%参与者NT-proBNP相对升高超过个体基线1.5倍。
- 无参与者超过450 pg/mL心血管并发症阈值,肌钙蛋白在所有评估的14天间期无变化。
- NT-proBNP升高与所评估协变量均无显著关联,男性、无新冠感染史或合并症者及接种mRNA-1273者呈非显著趋势。
临床怎么用
- 对健康成人接种mRNA新冠疫苗后出现的NT-proBNP短暂升高,可结合肌钙蛋白正常及无超标阈值判读为亚临床反应。
局限性
- 原文未明确列出局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiovascular complications such as myocarditis and pericarditis have been reported following mRNA COVID-19 vaccination, particularly after the second dose. However, little is known about the cardiac biomarker response in otherwise healthy individuals after mRNA COVID-19 vaccination. METHODS: This study aimed to investigate the dynamics of high-sensitivity cardiac troponins (hs-cTnI, hs-cTnT) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) following mRNA COVID-19 vaccination. We analyzed serum samples collected at multiple time points between April and December 2021 from 83 healthy adult military personnel vaccinated with two doses of mRNA COVID-19 vaccines. Statistical analyses included mixed-effects ANOVA with Geisser-Greenhouse correction and logistic regression to assess the influence of covariates. RESULTS: NT-proBNP levels showed a significant but transient increase, particularly within 14 days after the second vaccine dose (geometric mean 36.2 pg/mL; p < 0.0001). Nearly 49% of participants exhibited a relative increase exceeding 1.5 times their individual baseline. No participant surpassed the 450 pg/mL threshold indicative of cardiovascular complications, and troponin levels remained unchanged across all assessed 14-day intervals. The observed NT-proBNP elevation was not significantly associated with any of the assessed covariates. However, non-significant trends were noted among men, individuals without prior COVID-19 infection or comorbidities, and those vaccinated with the mRNA-1273 (Moderna) vaccine. CONCLUSIONS: In healthy adults, mRNA COVID-19 vaccination was associated with a short-term, subclinical elevation in NT-proBNP, particularly after the second dose. While not indicative of overt cardiovascular injury, this biomarker response may reflect transient myocardial stress and warrants further research.
引用
- Dlouhý P, Petráš M, Lesná IK, et al. Transient elevation of NT-proBNP after mRNA COVID-19 vaccination in healthy adults: A longitudinal biomarker analysis. Vaccine. 2026. PMID: 41905062. doi:10.1016/j.vaccine.2026.128535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。